Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Asset Writedowns and Impairment (2024 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Asset Writedowns and Impairment for 2 consecutive years, with $47.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Asset Writedowns and Impairment rose 2250.5% year-over-year to $47.0 million, compared with a TTM value of $49.6 million through Dec 2025, up 1846.43%, and an annual FY2025 reading of $58.7 million, up 921.75% over the prior year.
  • Asset Writedowns and Impairment was $47.0 million for Q3 2025 at Zevra Therapeutics, up from $546000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $47.0 million in Q3 2025 and bottomed at $546000.0 in Q4 2024.